HawkInsight

  • 联系我们
  • App
  • 中文

辉瑞终止血友病A基因治疗协议后,桑加莫股价暴跌38%

business

图画书

  • Sangamo Therapeutics (NASDAQ:SGMO) is 下降~38% in after-hours trading Monday after announcing that Pfizer (NYSE:PFE) is returning the development and commercialization rights to hemophilia A gene therapy candidate giroctocogene fitelparvovec.
  • 桑加莫表示,辉瑞已决定不再追求商业化

免责声明:本文观点来自原作者,不代表Hawk Insight的观点和立场。文章内容仅供参考、交流、学习,不构成投资建议。如涉及版权问题,请联系我们删除。